106.60
+0.4(+0.38%)
Currency In EUR
Address
Frankfurter Strasse 250
Darmstadt, 64293
Germany
Phone
49 6151 72 0
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
59020
First IPO Date
June 26, 1998
Name | Title | Pay | Year Born |
Dr. Kai Beckmann | Chief Executive Officer of Electronics & Member of the Executive Board | 4.99M | 1965 |
Dr. Matthias J. Heinzel | Chief Executive Officer of Life Science Sector & Member of Executive Board | 5.37M | 1967 |
Mr. Peter Guenter | Chief Executive Officer of Healthcare Business & Member of Executive Board | 5.76M | 1962 |
Ms. Belen Garijo Lopez M.D. | Chair of Executive Board & Chief Executive Officer | 6.79M | 1960 |
Ms. Helene von Roeder | Chief Financial Officer & Member of Executive Board | 3.52M | 1970 |
Dr. Michael Heckmeier | Head of the Display Materials Business Unit for Performance Materials | 0 | 1967 |
Mr. Frank Gotthardt | Head of Corporate & Government Relations - Europe | 0 | N/A |
Mr. Marc Horn | Head of Life Science Controlling | 0 | 1975 |
Mr. Dietmar Eidens | Head of the Global HR Business Partner Organization | 0 | 1958 |
Ms. Barbara Weiland | Chief Compliance Officer | 0 | 1974 |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.